Related Experiment Video

Updated: Mar 15, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

21.0K

A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in

Stéphanie Leroux1,2,3, Jean-Michel Roué4, Jean-Bernard Gouyon5

  • 1Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, APHP, Paris, France.

Antimicrobial Agents and Chemotherapy
|August 31, 2016
PubMed

Insights

This study optimized cefotaxime dosing for neonates by analyzing population pharmacokinetics. New guidelines ensure safer and more effective treatment for Gram-negative bacterial sepsis in infants.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Infectious Disease

Background:

  • Cefotaxime is a key antibiotic for neonatal Gram-negative bacterial sepsis.
  • Current dosing regimens in neonates lack standardization and may be suboptimal.

Purpose of the Study:

  • To conduct a population pharmacokinetic study of cefotaxime in neonates and young infants.
  • To evaluate and optimize cefotaxime dosing regimens for improved efficacy and safety.

Main Methods:

  • Population pharmacokinetic analysis using NONMEM software.
  • High-performance liquid chromatography-tandem mass spectrometry for drug concentration measurement.
  • Incorporation of developmental pharmacokinetics-pharmacodynamics, pathogens, and safety data.

Main Results:

  • An allometric two-compartment model with first-order elimination was used for 100 neonates.
  • Clearance and volume of distribution were 0.12 L/h/kg and 0.64 L/kg, respectively.
  • Weight, gestational age (GA), and postnatal age (PNA) significantly impacted cefotaxime pharmacokinetics.

Conclusions:

  • Current cefotaxime dosing underdoses older newborns.
  • A model-based regimen (50 mg/kg BID-QID based on GA and PNA) was established.
  • The proposed regimen has a minimal overdose risk (0.01%), optimizing neonatal treatment.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

7.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
636
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K